Effects of Transendocardial CD34+ Cell Transplantation on Diastolic Parameters in Patients with Nonischemic Dilated

Mojca Bervar1, Mirta Kozelj1, Gregor Poglajen2

  • 1Department of Cardiology.

Insights

CD34+ cell transplantation improved diastolic function in nonischemic dilated cardiomyopathy patients with elevated filling pressures. This stem cell therapy enhanced exercise capacity and reduced NT-proBNP levels in this patient group.

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Stem Cell Therapy

Background:

  • Diastolic dysfunction is a key issue in nonischemic dilated cardiomyopathy (DCM).
  • Elevated filling pressures (E/e' ≥ 15) in DCM patients correlate with myocardial scar and hibernation.
  • Understanding the physiological basis of diastolic dysfunction is crucial for effective treatment.

Purpose of the Study:

  • To evaluate the physiological background of diastolic parameters in nonischemic DCM patients.
  • To assess the effects of transendocardial CD34+ cell transplantation on diastolic function.
  • To determine if CD34+ cell therapy improves clinical outcomes in DCM.

Main Methods:

  • 38 DCM patients with NYHA class III and LVEF < 40% underwent transendocardial CD34+ cell transplantation.
  • Patients were divided into two groups based on baseline E/e' ratio (≥ 15 or < 15).
  • Evaluated diastolic parameters, myocardial scar, hibernation, 6-minute walk distance, and NT-proBNP levels over a 1-year follow-up.

Main Results:

  • Patients with higher baseline filling pressures (Group A) showed significant improvement in diastolic parameters (E/e') post-transplantation (p=0.005).
  • Group A also demonstrated increased 6-minute walk distance (p=0.03) and decreased NT-proBNP levels (p=0.02).
  • Diastolic dysfunction correlated with greater myocardial scar and hibernation in Group A.

Conclusions:

  • Diastolic dysfunction in nonischemic DCM is linked to myocardial scar and hibernation.
  • Transendocardial CD34+ cell transplantation shows potential to improve diastolic function and clinical outcomes in DCM patients.
  • This stem cell therapy may offer a novel therapeutic approach for managing nonischemic DCM.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
687
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
558
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
588